未治療の濾胞性リンパ腫の成人参加者を対象に、オドロネクタマブと化学療法の併用がリツキシマブと化学療法と比較してどの程度効果があるのか、またどの程度安全なのかを明らかにする研究 (OLYMPIA-2)
未治療の濾胞性リンパ腫参加者を対象に、抗CD20x抗CD3二重特異性抗体であるオドロネクタマブ(REGN1979)と化学療法の併用とリツキシマブと化学療法の併用の有効性と安全性を比較する第3相非盲検ランダム化試験(オリンピア) 2)
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma. Follicular lymphoma is a type of non-Hodgkin lymphoma or NHL. Participants with follicular lymphoma that has come back after treatment (called "relapsed") or did not respond to treatment (called "refractory") are eligible to take part only in Part 1A of the study.
This study is made up of 3 parts: Part 1A (non-randomized), Part 1B and Part 2 (randomized - controlled).
The aim of Part 1A and Part 1B of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the dose and schedule of the study drug to be combined with chemotherapy to be used in Part 2 of the study.
The aim of Part 2 of the study is to assess how effective the combination of the study drug with chemotherapy is in comparison with the combination of rituximab and chemotherapy (the current standard-of-care for NHL). Standard-of-care means the usual medication expected and used when receiving treatment for a condition.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
- The impact from the study drug on quality-of-life and ability to complete routine daily activities
調査の概要
状態
条件
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Florida
-
Plantation、Florida、アメリカ、33322
- Boca Raton Clinical Research (BRCR) Global
-
-
Indiana
-
Noblesville、Indiana、アメリカ、46062
- Investigative Clinical Research of Indiana
-
-
Kansas
-
Wichita、Kansas、アメリカ、67214
- Cancer Center of Kansas
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40536
- University of Kentucky
-
-
Michigan
-
Detroit、Michigan、アメリカ、48202
- Henry Ford Health System
-
Grand Rapids、Michigan、アメリカ、49503
- Cancer and Hematology Centers of Western Michigan
-
-
Texas
-
Houston、Texas、アメリカ、77030
- Center for Oncology and Blood Disorders
-
-
Utah
-
Ogden、Utah、アメリカ、84405
- Community Cancer Trials of Utah
-
-
Wisconsin
-
Waukesha、Wisconsin、アメリカ、53188
- Prohealth Care Inc
-
-
-
-
-
Aberdeen、イギリス、AB25 2ZN
- NHS Grampian: Aberdeen Royal Infirmary
-
-
Cornwall
-
Truro、Cornwall、イギリス、TR1 3LJ
- Royal Cornwall Hospitals NHS Trust, Royal Cornwall Hospital
-
-
London
-
Uxbridge、London、イギリス、UB8 3NN
- The Hillingdon Hospitals NHS Foundation Trust
-
-
West Midlands
-
Birmingham、West Midlands、イギリス、B15 2SY
- University Hospitals Birmingham NHS Foundation Trust
-
-
-
-
-
Beersheba、イスラエル、84101
- Soroka University Medical Center
-
Haifa、イスラエル、3109601
- Rambam Health Care Campus
-
Jerusalem、イスラエル、91200
- Hadassah Medical Center
-
Petah Tikva、イスラエル、49100
- Rabin Medical Center
-
Tel Aviv、イスラエル、64239
- The Tel Aviv Sourasky Medical Center
-
Tel Aviv、イスラエル、6971028
- Assuta Medical Centers
-
-
Jerusalem
-
Jerusalem、Jerusalem、イスラエル、9103102
- Shaare Zedek Medical Center
-
-
-
-
-
Milan、イタリア、20141
- Istituto Europeo di Oncologia
-
Milan、イタリア、20162
- ASST Grande Ospedale Metropolitano Niguarda - Main Address
-
Milan、イタリア、20122
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
Modena、イタリア、41124
- A.O.U. di Modena
-
Naples、イタリア、80131
- Federico II University
-
Perugia、イタリア、06132
- Azienda Ospedaliera di Perugia
-
Pisa、イタリア、56126
- University of Pisa, Section of Hematology
-
Potenza、イタリア、85100
- Azienda Ospedaliera Regionale San Carlo
-
Ravenna、イタリア、48121
- UO Ematologia Ravenna
-
Reggio Emilia、イタリア、42123
- Azienda Unita Sanitaria Locale Irccs Arcispedale Santa Maria Nuova
-
Rome、イタリア、00161
- Azienda Osperdaliero-Universitaria Policlinico Umberto 1
-
Udine、イタリア、33100
- Azienda Sanitaria Universitaria del Friuli Centrale
-
-
Forli-Cesena
-
Meldola、Forli-Cesena、イタリア、47014
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
-
-
Piedmont
-
Turin、Piedmont、イタリア、10137
- Azienda Ospedaliera Ordine Mauriziano Torino, Presidio Umberto I of Turin
-
-
Sicily
-
Palermo、Sicily、イタリア、90127
- Azienda Ospedaliera Universitario Policlinico Palermo
-
-
-
-
New South Wales
-
Liverpool、New South Wales、オーストラリア、2170
- Liverpool Hospital
-
Waratah、New South Wales、オーストラリア、2298
- Calvary Mater Newcastle
-
-
Queensland
-
Benowa、Queensland、オーストラリア、4217
- Pindara Private Hospital
-
-
-
-
-
Vienna、オーストリア、1090
- Universitatsklinik fur Kinder und Jungendheilkunde
-
Wels、オーストリア、4600
- Klinikum Wels-Grieskirchen
-
-
Lower Austria
-
Sankt Pölten、Lower Austria、オーストリア、3100
- Karl Landsteiner University Hospital St. Poelten
-
-
Styria
-
Graz、Styria、オーストリア、8036
- Medical University of Graz
-
Leoben、Styria、オーストリア、8700
- Landeskrankenhaus Hochsteiermark
-
-
Tyrol
-
Innsbruck、Tyrol、オーストリア、6020
- Innsbruck Medical University
-
-
Upper Austria
-
Linz、Upper Austria、オーストリア、4020
- Kepler University Hospital
-
-
-
-
-
Lugo、スペイン、27003
- Hospital Universitario Lucus Augusti
-
Madrid、スペイン、28027
- Clinica Universidad de Navarra - Madrid
-
Madrid、スペイン、28034
- Hospital Universitario Ramon y Cajal
-
Madrid、スペイン、28041
- Hospital Universitario 12 de Octubre
-
Madrid、スペイン、28031
- Hospital Universitario Infanta Leonor
-
Madrid、スペイン、28040
- Hospital Universitario Fundacion Jimenez Diaz
-
Ourense、スペイン、32005
- Complexo Hospitalario Universitario de Ourense
-
Pamplona、スペイン、31008
- Clinica Universidad de Navarra- Pamplona
-
Salamanca、スペイン、37007
- Hospital Universitario de Salamanca
-
Seville、スペイン、41009
- Hospital Universitario Virgen Macarena
-
Valencia、スペイン、46009
- Instituto Valenciano de Oncologia
-
Valencia、スペイン、46010
- Hospital Clinico Universitario de Valencia
-
-
Andalusia
-
Seville、Andalusia、スペイン、41013
- Hospital Universitario Virgen del Rocio
-
-
Barcelona
-
Sabadell、Barcelona、スペイン、08208
- Parc Tauli Sabadell Hospital Universitari
-
Terrassa、Barcelona、スペイン、08221
- Hospital Universitari Mutua Terrassa
-
-
Bizkaia
-
Barakaldo、Bizkaia、スペイン、48903
- Cruces University Hospital (Hospital Universitario Cruces)
-
-
Madrid
-
Majadahonda、Madrid、スペイン、28222
- Hospital Universitario Puerta de Hierro - Majadahonda
-
Pozuelo de Alarcón、Madrid、スペイン、28223
- Hospital Universitario Quiron Salud Madrid
-
-
Navarre
-
Pamplona、Navarre、スペイン、31008
- Hospital Universitario de Navarra
-
-
Principality of Asturias
-
Oviedo、Principality of Asturias、スペイン、33011
- Hospital Universitario Central de Asturias
-
-
Valencia
-
Alicante、Valencia、スペイン、03010
- Hospital General Universitario Doctor Balmis Alicante
-
-
-
-
-
Khon Kaen、タイ、40002
- Khon Kaen University
-
-
Krung Thep Maha Nakhon [Bangko]
-
Bangkok、Krung Thep Maha Nakhon [Bangko]、タイ、10330
- Chulalongkorn University
-
-
-
-
North Central Czech Republic
-
Hradec Králové、North Central Czech Republic、チェコ、50005
- University Hospital Hradec Kralove
-
-
South Moravian
-
Brno、South Moravian、チェコ、62500
- University Hospital Brno
-
-
-
-
Las Condes
-
Santiago、Las Condes、チリ、7620157
- Hospital Clinico Universidad de Los Andes
-
-
Santiago Metropolitan
-
Santiago、Santiago Metropolitan、チリ、7560907
- Centro Oncologia de Precision Universidad Mayor
-
Santiago、Santiago Metropolitan、チリ、7580206
- Inmunocel
-
Santiago、Santiago Metropolitan、チリ、7550000
- Pontificia Universidad Catolica de Chile
-
-
-
-
-
Ankara、トルコ(Türkiye)、06100
- Liv Hospital Ankara
-
Istanbul、トルコ(Türkiye)、34365
- VKV American Hopital
-
Istanbul、トルコ(Türkiye)、34418
- Istanbul University
-
Kayseri、トルコ(Türkiye)、38039
- Erci̇yes Uni̇versi̇ty
-
Samsun、トルコ(Türkiye)、55270
- Ondokuz Mayıs University
-
Zonguldak、トルコ(Türkiye)、67100
- Zonguldak Bulent Ecevit University
-
-
Ankara
-
Mamak、Ankara、トルコ(Türkiye)、06620
- Ankara University Faculty of Medicine
-
Yenimahalle、Ankara、トルコ(Türkiye)、06200
- Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
-
Central Anatolia
-
Ankara、Central Anatolia、トルコ(Türkiye)、06100
- Gazi University
-
-
Mersin
-
Mezitli、Mersin、トルコ(Türkiye)、33200
- VM Medical Park Mersin Hospital
-
-
Serdivan
-
Sakarya、Serdivan、トルコ(Türkiye)、54050
- Sakarya University
-
-
Suleymanpasa
-
Tekirdağ、Suleymanpasa、トルコ(Türkiye)、59100
- Tekirdag Namik Kemal University Hospital
-
-
-
-
-
Kiel、ドイツ、24116
- Stadtisches Krankenhaus Kiel
-
Neuss、ドイツ、41462
- MVZ fuer Haematologie und Onkologie Rhein-Kreis GmbH
-
-
-
-
-
Grenoble、フランス、38043
- Centre Hospitalier Universitaire de Grenoble
-
Le Puy-en-Velay、フランス、43012
- Centre Hospitalier Emile Roux
-
Lens、フランス、62300
- Centre Hospitalier de Lens (Centre Hospitalier Dr Schaffner dLens)
-
Paris、フランス、75010
- Hopital Saint Louis
-
Pessac、フランス、33600
- Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Sud - Hôpital Haut Lévêque
-
Saint-Etienne、フランス、42055
- CHU de Saint-Etienne
-
Saint-Nazaire、フランス、44600
- Centre Hospitalier de Saint Nazaire
-
-
Alpes Maritimes
-
Cannes、Alpes Maritimes、フランス、06400
- Cannes Hospital (Centre Hospitalier Cannes Simone Veil)
-
-
Centre-Val de Loire
-
Tours、Centre-Val de Loire、フランス、37044
- CHRU de Tours
-
-
Gard
-
Nîmes、Gard、フランス、30029
- Institut de Cancerologie du Gard
-
-
New Aquitaine
-
Mont-de-Marsan、New Aquitaine、フランス、40024
- Centre Hospitalier de Mont-de-Marsan
-
-
Pays de la Loire Region
-
Nantes、Pays de la Loire Region、フランス、44093
- Nantes University Hospital
-
-
Pontoise
-
Cergy-Pontoise、Pontoise、フランス、95300
- The Novo Hospital North West Val Deoise
-
-
Île-de-France Region
-
Argenteuil、Île-de-France Region、フランス、95100
- Hopital Victor Dupouy Argenteuil
-
-
-
-
-
Rio de Janeiro、ブラジル、20231050
- Instituto Nacional de Cancer Jose Alencar Gomes da Silva
-
São Paulo、ブラジル、01323-903
- Hospital Alemao Oswaldo Cruz
-
São Paulo、ブラジル、08270-070
- Casa de Saude Santa Marcelina
-
São Paulo、ブラジル、01509-010
- AC Camargo Cancer Center
-
São Paulo、ブラジル、05403-000
- Clinical Hospital of Medicine School at Sao Paulo University
-
-
Estado de Bahia
-
Salvador、Estado de Bahia、ブラジル、41253-900
- Hospital Sao Rafael
-
Salvador、Estado de Bahia、ブラジル、41950-640
- Ensino e Terapia de Inovacao Clinica Amo (Etica)
-
Salvador、Estado de Bahia、ブラジル、40050-410
- Hospital Santa Izabel - Santa Casa de Misericordia da Bahia
-
-
Federal District
-
Brasília、Federal District、ブラジル、70200-730
- Hospital Sirio Libanes Brasilia
-
Brasília、Federal District、ブラジル、70390-140
- Instituto DOr de Pesquisa e Ensino Df Star
-
-
Minas Gerais
-
Belo Horizonte、Minas Gerais、ブラジル、30380-472
- Instituto Mario Pena de Ensino Pesquisa e Inovacao
-
Uberlândia、Minas Gerais、ブラジル、38408-008
- Centro Oncologico do Triangulo (COT) - Uberlandia
-
-
Paraná
-
Curitiba、Paraná、ブラジル、81520-060
- Hospital Erasto Gaertner
-
-
Rio Grande do Norte
-
Natal、Rio Grande do Norte、ブラジル、59062-000
- Liga Norte Riograndense Contra o Cancer
-
-
Rio Grande do Sul
-
Bento Gonçalves、Rio Grande do Sul、ブラジル、95700-084
- Instituto Tacchini de Pesquisa em Saude
-
Passo Fundo、Rio Grande do Sul、ブラジル、99010-080
- Instituto do Cancer em Hospital Sao Vicente de Paulo
-
Porto Alegre、Rio Grande do Sul、ブラジル、90035-903
- Hospital de Clinicas de Porto Alegre
-
-
Santa Catarina
-
Joinville、Santa Catarina、ブラジル、89201-260
- Centro de Hematologia e Oncologia
-
Lages、Santa Catarina、ブラジル、88501-001
- Animi Unidade de Tratamento Oncologico Ltda
-
-
São Paulo
-
Barretos、São Paulo、ブラジル、14784-400
- Fundacao Pio XII Hospital de Amor
-
Jaú、São Paulo、ブラジル、17210-080
- Amaral Carvalho Hospital
-
Ribeirão Preto、São Paulo、ブラジル、14048-900
- Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto
-
-
-
-
-
Brussels、ベルギー、1000
- Institut Jules Bordet
-
Liège、ベルギー、4000
- Centre Hospitalier Regional de la Citadelle
-
-
Oost-Vlaanderen
-
Ghent、Oost-Vlaanderen、ベルギー、9000
- Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital
-
Sint-Niklaas、Oost-Vlaanderen、ベルギー、9100
- Verenigde Ziekenhuizen van Waas en Durme
-
-
West-Vlaanderen
-
Bruges、West-Vlaanderen、ベルギー、8000
- Algemeen Ziekenhuis St Jan Brugge Oostende Av
-
Kortrijk、West-Vlaanderen、ベルギー、8500
- AZ Groeninge
-
-
-
-
-
Bydgoszcz、ポーランド、85-168
- Szpital Uniwersytecki Nr2 Bydgoszcz
-
Gdansk、ポーランド、80-952
- Uniwersyteckie Centrum Kliniczne, Building of the Non-Invasive Medicine Center
-
Katowice、ポーランド、40-519
- Pratia Onkologia Katowice
-
Lodz、ポーランド、93-513
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. Mikolaja Kopernika w Lodzi (Copernicus Memorial Hospital)
-
Lublin、ポーランド、20-954
- Centrum Innowacyjnych Terapii Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie
-
Warsaw、ポーランド、02781
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy Warszawa
-
Wałbrzych、ポーランド、58-300
- Szpital Szpecjalistyczny w Walbrzychu
-
-
Lesser Poland Voivodeship
-
Krakow、Lesser Poland Voivodeship、ポーランド、30-510
- Matopolskie Centrum Medyczne S.C.
-
-
Wielkopolska
-
Skorzewo、Wielkopolska、ポーランド、60185
- Aidport Sp. z o.o.
-
-
-
-
-
Kaohsiung City、台湾、83301
- Kaohsiung Chang Gung Memorial Hospital
-
Kaohsiung City、台湾、80756
- Kaohsiung Medical University Hospital
-
New Taipei City、台湾、23561
- Taipei Medical University - Shuang Ho Hospital
-
Taipei、台湾、11217
- Taipei Veterans General Hospital
-
Taipei、台湾、11490
- Tri-Service General Hospital
-
Taipei、台湾、11696
- Taipei Medical University Multipal Wan Fang University
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
-
Have diagnosis of cluster of differentiation 20 positive (CD20+) FL grade 1-3a, stage II bulky or stage III / IV
- For Part 1A: previously untreated participants who have Follicular Lymphoma International Prognostic Index (FLIPI)-1 score of 3 to 5, or R/R FL
- For Part 1B: previously untreated participants who have FLIPI-1 score of 3 to 5
- For Part 2: previously untreated participants who have FLIPI-1 score of 0 to 5
-
Have measurable disease on cross sectional imaging documented by diagnostic computed tomography [CT], or magnetic resonance imaging [MRI] imaging, as described in the protocol
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
-
Adequate bone marrow and hepatic function.
Key Exclusion Criteria:
- Participants with central nervous system lymphoma or leptomeningeal lymphoma
- Participants with histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma
- Participants with Waldenström macroglobulinemia (WM, lymphoplasmacytic lymphoma), grade 3b follicular lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma
- Recent major surgery and history or organ transplantation
- A malignancy other than NHL unless the participant is adequately and definitively treated and any other significant active disease or medical condition that could interfere with the conduct of the study or put the participant at significant risk, as described in the protocol.
Note: Other protocol-defined Inclusion/Exclusion criteria apply
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Odronextamab + Chemotherapy
Part 1 of the study includes ordonextamab dose escalation for participants with previously untreated FL and relapsed/refractory FL (Part 1A only) followed by a randomized exploration of 2 regimens of odronextamab (Odro) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) with the objective of dose optimization (Part 1B) in previously untreated patients with FL. |
Administered by intravenous (IV) infusion
他の名前:
Administered by IV infusion
他の名前:
Administered by IV infusion
他の名前:
Administered orally (PO)
他の名前:
|
|
アクティブコンパレータ:Rituximab + Chemotherapy
In Part 2 only, participants will be randomized 1:1:1 to receive rituximab (R) with chemotherapy (CHOP), followed by rituximab monotherapy maintenance. |
Administered by intravenous (IV) infusion
他の名前:
Administered by IV infusion
他の名前:
Administered by IV infusion
他の名前:
Administered orally (PO)
他の名前:
Administered by IV infusion, or subcutaneous (SC)
他の名前:
Administered by IV infusion
他の名前:
|
|
実験的:Odronextamab + Chemotherapy + Maintenance
In Part 2, participants will be randomized 1:1:1 to receive odronextamab with chemotherapy [CHOP, or cyclophosphamide, vincristine, and prednisone (CVP)], followed by odronextamab monotherapy maintenance. |
Administered by intravenous (IV) infusion
他の名前:
Administered by IV infusion
他の名前:
|
|
実験的:Odronextamab + Chemotherapy + No maintenance
In Part 2, participants will be randomized 1:1:1 to receive odronextamab with chemotherapy (CHOP, or CVP) without maintenance. |
Administered by intravenous (IV) infusion
他の名前:
Administered by IV infusion
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of dose limiting toxicities (DLTs) for odronextamab in combination with chemotherapy
時間枠:Up to 35 days
|
Part 1, DLT period |
Up to 35 days
|
|
Incidence of treatment-emergent adverse events (TEAEs) of odronextamab in combination with chemotherapy
時間枠:Up to 2 years
|
Part 1, Treatment period |
Up to 2 years
|
|
Severity of TEAEs of odronextamab in combination with chemotherapy
時間枠:Up to 2 years
|
Part 1, Treatment period |
Up to 2 years
|
|
Complete Response rate at 30 months (CR30) assessed by independent central review (ICR)
時間枠:Up to 30 months
|
Part 2 |
Up to 30 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Survival (OS)
時間枠:Up to 5 years
|
Part 2 |
Up to 5 years
|
|
CR30 as assessed by local investigator
時間枠:Up to 30 months
|
Part 2 |
Up to 30 months
|
|
Incidence of TEAEs
時間枠:Up to 2 years
|
Part 2 |
Up to 2 years
|
|
Severity of TEAEs
時間枠:Up to 2 years
|
Part 2 |
Up to 2 years
|
|
Change in Patient Global Impression of Severity (PGIS)
時間枠:Up to 5 years
|
Part 2 The PGIS includes a single-item to assess how a patient perceives the overall severity of cancer symptoms over the past 7 days. Patients will choose the response that best describes the severity of their overall cancer symptoms with options on a 5-point scale ranging from 1 (No symptoms) to 4 (Very Severe). |
Up to 5 years
|
|
Change in Patient Global Impression of Change (PGIC)
時間枠:Up to 5 years
|
Part 2 The PGIC item includes a single-item to assess how a patient perceives their overall change in health status since the start of study treatment. Patients will choose from response options on a 7-point scale ranging from 1 (Much Better) to 7 (Much worse); 1- Much Better, 2-Moderately Better, 3-A Little Better, 4-About the Same, 5-A Little Worse, 6-Moderately Worse, 7-Much Worse. |
Up to 5 years
|
|
BOR as assessed by ICR
時間枠:Up to 30 months
|
Part 2 |
Up to 30 months
|
|
Odronextamab concentrations in serum when administered with chemotherapy
時間枠:Up to 30 months
|
Part 1, Maintenance period and Part 2, Induction period |
Up to 30 months
|
|
Odronextamab concentrations in serum when administered as monotherapy
時間枠:Up to 30 months
|
Part 1 and Part 2, Maintenance period |
Up to 30 months
|
|
Incidence of anti-odronextamab antibodies (ADAs)
時間枠:Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Titers of ADAs to odronextamab
時間枠:Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Incidence of neutralizing antibodies (NAb) to odronextamab
時間枠:Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Best overall response (BOR) as assessed by the investigator
時間枠:Up to 30 months
|
Part 1, end of Induction period and end of Maintenance period |
Up to 30 months
|
|
Progression free survival (PFS) as assessed by ICR
時間枠:Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Change in patient reported physical functioning scale scores on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Cancer-30 (EORTC-QLQ-C30)
時間枠:Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a global health status (GHS)/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
PFS as assessed by local investigator
時間枠:Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Event-free survival (EFS) as assessed by ICR
時間枠:Up to 5 years
|
Part 2 |
Up to 5 years
|
|
EFS as assessed by local investigator
時間枠:Up to 5 years
|
Part 2 |
Up to 5 years
|
|
BOR as assessed by local investigator
時間枠:Up to 30 months
|
Part 2 |
Up to 30 months
|
|
Duration of response (DOR) assessed by ICR
時間枠:Up to 5 years
|
Part 2 |
Up to 5 years
|
|
DOR as assessed by local investigator
時間枠:Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Time to next anti-lymphoma treatment (TTNT)
時間枠:Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Change in patient reported health related quality of life (HRQoL) as measured by EORTC-QLQ-C30
時間枠:Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
Change in cancer disease as measured by EORTC-QLQ-C30
時間枠:Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
Change in treatment related symptoms as measured by EORTC-QLQ-C30
時間枠:Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
Change in patient-reported lymphoma disease as measured by the Lymphoma Subscale of the Functional Assessment of Cancer Treatment-Lymphoma (FACT-LymS)
時間枠:Up to 5 years
|
Part 2 The FACT-Lym lymphoma subscale (LymS) includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life. |
Up to 5 years
|
|
Change in treatment-related symptoms as measured by the FACT-LymS
時間枠:Up to 5 years
|
Part 2 The FACT-LymS includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life. |
Up to 5 years
|
|
Change in patient-reported general health status per EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)
時間枠:Up to 5 years
|
Part 2 The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: "no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems". The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labeled "Best imaginable health state" and "Worst imaginable health state". |
Up to 5 years
|
|
Change in patient-reported treatment side effects burden per Functional Assessment of Cancer Therapy-General Global Population Item 5 (FACT-G GP5)
時間枠:Up to 5 years
|
Part 2 A single item GP5 of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4). |
Up to 5 years
|
|
Change in score of the FACT-G GP5 item in the patient population
時間枠:Up to 5 years
|
Part 2 A single item GP5 of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4). |
Up to 5 years
|
協力者と研究者
捜査官
- スタディディレクター:Clinical Trial Management、Regeneron Pharmaceuticals
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 病理学的プロセス
- 新生物
- 疾患の属性
- 免疫系疾患
- 組織型別の新生物
- リンパ疾患
- リンパ増殖性疾患
- 免疫増殖性疾患
- リンパ腫、非ホジキン
- リンパ腫
- 病理学的状態、徴候および症状
- ヘミックおよびリンパ疾患
- 再発
- リンパ腫、濾胞性
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 有機化学物質
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- 炭化水素
- 炭化水素、周期的
- 炭水化物
- アルカロイド
- 多環芳香族炭化水素
- 炭化水素、芳香
- 多環式化合物
- グリコシド
- インドール
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- 妊娠
- 妊娠
- ステロイド
- 融合リング化合物
- ホスホルアミドマスタード
- 窒素マスタード化合物
- マスタード化合物
- 炭化水素、ハロゲン化
- ホスホラミド
- 有機リン化合物
- 妊娠症
- 妊娠した
- ヴィンカアルカロイド
- セコロガニントリプタミンアルカロイド
- インドールアルカロイド
- インドリジジン
- インドリジン
- アントラサイクリン
- ナフテセン
- アミノグリコシド
- 抗体、モノクローナル、マウス由来
- ダウノルビシン
- プレドニゾロン
- リツキシマブ
- プレドニン
- シクロホスファミド
- ドキソルビシン
- ビンクリスチン
- メチルプレドニゾロン
その他の研究ID番号
- R1979-ONC-2075
- 2022-502113-28-00 (その他の識別子:EUCT Number)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD 共有時間枠
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD 共有アクセス基準
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。